Systemic lupus erythematosus and associated healthcare resource consumption in selected cities from the Russian Federation, Republic of Kazakhstan and Ukraine: the ESSENCE study

被引:3
|
作者
Nasonov, E. [1 ]
Soloviev, S. [1 ]
Davidson, J. E. [2 ]
Lila, A. [3 ]
Togizbayev, G. [4 ]
Ivanova, R. [5 ]
Baimukhamedov, Ch [4 ]
Omarbekova, Zh [4 ]
Laremenko, O. [6 ]
Gnylorybov, A. [7 ]
Shevchuk, S. [8 ]
Vasylyev, A. [9 ]
Makarova, J. [10 ]
Tariq, L. [11 ]
机构
[1] Russian Acad Med Sci, Inst Rheumatol, Moscow, Russia
[2] GlaxoSmithKline R&D, Worldwide Epidemiol, Stockley Pk, Uxbridge, Middx, England
[3] North Western Med Univ, St Petersburg, Russia
[4] Inst Adv Educ Asyl Clin, Alma Ata, Kazakhstan
[5] Semey State Med Univ, Internal Med Dept, Semey, Kazakhstan
[6] Natl Med Univ, Kiev, Ukraine
[7] Natl Acad Med Sci Ukraine, Inst Urgent & Recovery Surg, Kiev, Ukraine
[8] Vinnytsya Natl Med Univ, Sci Res Inst Rehabil Disabled, Vinnitsya, Ukraine
[9] GlaxoSmithKline, Kiev, Ukraine
[10] GlaxoSmithKline, Moscow, Russia
[11] GlaxoSmithKline, Dubai, U Arab Emirates
关键词
Systemic Lupus Erythematosus; SLE; healthcare resource consumption; Russia; Kazakhstan; Ukraine; COSTS; SLE; NEPHRITIS; COUNTRIES; ETHNICITY; IMPACT;
D O I
10.1080/13696998.2018.1499518
中图分类号
F [经济];
学科分类号
02 ;
摘要
Objectives: To evaluate healthcare resource (HR) consumption associated with Systemic Lupus Erythematosus (SLE) management in adult patients with active autoantibody positive disease in the Russian Federation, Republic of Kazakhstan, and Ukraine. Methods: The ESSENCE was a retrospective, observational study, and included data on patients' clinical characteristics and SLE-related HR use (laboratory, biopsy, imaging tests, medications, visits to specialists, outpatient visits, hospitalizations) during 2010 from the 12 specialized rheumatologic centers. Results: A total of 436 SLE patients were included in the analyses, with 232 patients being enrolled in Russia, 110 in Kazakhstan, and 94 in Ukraine. The mean age was 36-42 years and median SLE duration was 3-6.8 years across the countries. Extrapolation to total country population showed that, in 2010, visits to specialists (who assign treatment for organs involved/damaged by SLE) were the most frequently used HR (from 13,439 visits in Kazakhstan to 23,510 in Russia), followed by hospitalizations (from 2,950 in Kazakhstan to 6,267 in Russia) and outpatient visits (from 1,654 visits in Russia to 8,064 in Kazakhstan). Compared to chronic active patients (SLE persistent during last year), patients with relapsing-remitting SLE (at least one flare alternated by one remission per year) had a higher rate of visits to specialists (100% vs 60.8%, p < .001) and hospitalizations (98.9% vs 60.8%, p < .001). Compared to patients without flares, patients experiencing flares had a higher rate of unplanned visits to specialists (86.2% vs 6.3%, p < .001), were more often hospitalized (both ICU and non-ICU) (100.0% vs 50.0%, p < .001), and had a longer duration of ICU hospitalization (25.9 days vs 17.5 days, p < .001). Conclusions: Specialist visits are the most frequently consumed SLE-related healthcare recourse in the Commonwealth of Independent States (CIS) countries. A relapsing-remitting SLE profile and the occurrence of flares significantly raise healthcare resource consumption.
引用
收藏
页码:1006 / 1015
页数:10
相关论文
共 37 条
  • [1] Standard medical care of patients with systemic lupus erythematosus (SLE) in large specialised centres: data from the Russian Federation, Ukraine and Republic of Kazakhstan (ESSENCE)
    Nasonov, E.
    Soloviev, S.
    Davidson, J. E.
    Lila, A.
    Togizbayev, G.
    Ivanova, R.
    Baimukhamedov, Ch
    Omarbekova, Zh
    Iaremenko, O.
    Gnylorybov, A.
    Shevchuk, S.
    Vasylyev, A.
    Pereira, M. H. S.
    LUPUS SCIENCE & MEDICINE, 2015, 2 (01):
  • [2] The prevalence and incidence of Systemic Lupus Erythematosus (SLE) in selected cities from three Commonwealth of Independent States countries (the Russian Federation, Ukraine and Kazakhstan)
    Nasonov, E.
    Soloviev, S.
    Davidson, J. E.
    Lila, A.
    Ivanova, R.
    Togizbayev, G.
    Omarbekova, Z.
    Shevchuk, S.
    Iaremenko, O.
    Gnylorybov, A.
    Smailova, Z.
    Chernogolov, V.
    Malynovska, K.
    Vasylyev, A.
    Pereira, M. H. S.
    LUPUS, 2014, 23 (02) : 213 - 219
  • [3] Standard medical care of patients with systemic lupus erythematosus (SLE) in large specialised centres: data from the Russian Federation, Ukraine and Republic of Kazakhstan (ESSENCE) (vol 2, e000060, 2015)
    Nasonov, E.
    Soloviev, S.
    Davidson, J. E.
    LUPUS SCIENCE & MEDICINE, 2015, 2 (01):
  • [4] FACTORS AFFECTING QUALITY OF LIFE IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS IN 1102 LUPUS PATIENTS FROM THE RUSSIAN FEDERATION (RF), KIRGHIZSTAN AND KAZAKHSTAN
    Aseeva, E.
    Solovyev, S.
    Koilubaeva, G.
    Issayeva, B.
    Glukhova, S.
    Lila, A.
    ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 : 1368 - 1369
  • [5] Healthcare Resource Utilization and Associated Costs in Patients With Systemic Lupus Erythematosus Diagnosed With Lupus Nephritis
    Bell, Christopher F.
    Wu, Benjamin
    Huang, Shirley P.
    Rubin, Bernard
    Averell, Carlyne M.
    Chastek, Benjamin
    Hulbert, Erin M.
    Von Feldt, Joan
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2023, 15 (04)
  • [6] CLINICAL FEATURES AND TREATMENT OF 1102 PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS IN THE RUSSIAN FEDERATION (RF), KIRGIZSTAN AND KAZAKHSTAN IN REAL CLINICAL PRACTICE (RENAISSANCE COHORT)
    Aseeva, E.
    Solovyev, S.
    Koilubaeva, G.
    Issayeva, B.
    Saparbayeva, M.
    Nikishina, N.
    Mesnyankina, A.
    Lila, A.
    ANNALS OF THE RHEUMATIC DISEASES, 2021, 80 : 1185 - 1185
  • [7] Adverse Outcomes, Healthcare Resource Utilization, and Costs Associated with Systemic Corticosteroid use Among Adults with Systemic Lupus Erythematosus in the UK
    Stirnadel-Farrant, Heide A.
    Golam, Sarowar M.
    Naisbett-Groet, Barbara
    Gibson, Danny
    Langham, Julia
    Langham, Sue
    Samnaliev, Mihail
    RHEUMATOLOGY AND THERAPY, 2023, 10 (05) : 1167 - 1182
  • [8] Adverse Outcomes, Healthcare Resource Utilization, and Costs Associated with Systemic Corticosteroid use Among Adults with Systemic Lupus Erythematosus in the UK
    Heide A. Stirnadel-Farrant
    Sarowar M. Golam
    Barbara Naisbett-Groet
    Danny Gibson
    Julia Langham
    Sue Langham
    Mihail Samnaliev
    Rheumatology and Therapy, 2023, 10 : 1167 - 1182
  • [9] A REAL-WORLD STUDY OF HEALTHCARE RESOURCE UTILIZATION AND COSTS FOR SYSTEMIC LUPUS ERYTHEMATOSUS PATIENTS IN TAIWAN
    Tang, C. H.
    Chang, Y. S.
    Ng, K. J.
    Chuang, P. Y.
    Furnback, W.
    Wang, B.
    Wei, A.
    Treuer, T.
    VALUE IN HEALTH, 2022, 25 (07) : S599 - S600
  • [10] Healthcare resource utilization and costs associated with long-term corticosteroid exposure in patients with systemic lupus erythematosus
    Kabadi, S.
    Yeaw, J.
    Bacani, A. K.
    Tafesse, E.
    Bos, K.
    Karkare, S.
    DeKoven, M.
    Vina, E. R.
    LUPUS, 2018, 27 (11) : 1799 - 1809